ITMCTR2200005669尚未招募4 期
Clinical study on NIH-CPSI score of Xialiqi capsule ameliorating Type III Prostatitis ( Syndrome of Spleen-Kidney Qi Deficiency and Damp-Heat Stasis)
试验速览
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional study
入排标准
- 年龄范围
- 18 至 50（—）
- 性别
- Male
入选标准
- •(1) It conforms to the diagnostic criteria of Type III Prostatitis.
- •(2) It conforms to the standard of Syndrome of Spleen-Kidney Qi Deficiency and Damp-Heat Stasis.
- •(3) Aged between 18 and 50.
- •(4) NIH-CPSI=10.
- •(5) Voluntarily participate in the study and sign the informed consent.
排除标准
- •(1) Patients with type I, II and IV prostatitis.
- •(2) Those who have used drugs or other related treatments for chronic prostatitis in the past 2 weeks.
- •(3) Patients with benign prostatic hyperplasia, prostate tumor, epididymitis, seminal vesiculitis, urinary tract disease, severe neurosis diabetes, pelvic surgery history, etc.
- •(4) Patients with coronary heart disease, serious primary cardiovascular disease, liver disease, kidney disease, hematologic disease, pulmonary disease, or serious disease affecting their survival, such as tumor or AIDS, should not be selected.
- •(5) ALT, AST or BUN exceeding 2 times the upper limit of normal value, or eGFR<45ml/min/1.73m2.
- •(6) Postural hypotension.
- •(7) Non-prostatitis caused by the lower abdomen, perineum, lumbosacral and other painful diseases.
- •(8) Patients with allergic constitution or allergy to test drug composition, and patients with a history of sulfonamide drug allergy.
- •(9) Suspected or had a history of alcohol or drug abuse, or had other diseases that, according to the judgment of the investigator, reduced the possibility of enrollment or complicated enrollment, such as frequent changes in the work environment, which could easily lead to loss of follow-up.
- •(10) Patients receiving CYP3A4 or CYP2D6 potent inhibitors (such as Ketoconazole and paroxetine), other adrenergic blockers and cimetidine.
- •(11) Patients who are participating in clinical trials of other drugs, or have participated in a drug clinical trial within the past one month.
- •(12) Other patients deemed unsuitable for the clinical study by the investigator.
研究者
相似试验
尚未招募
1 期
Clinical study of Shenyuan Yiqi Huoxue Capsule on cardiopulmonary motor function and quality of life in patients with Ischemic CardiomyopathyIschemic cardiomyopathyITMCTR2200006813Beijing Hospital of Traditional Chinese Medicine Affiliated to Capital Medical University
招募中
4 期
Therapeutic effect of Xialiqi Capsule on benign prostatic hyperplasiabenign prostatic hyperplasiaITMCTR2100005234Second Hospital of Tianjin Medical University
尚未招募
4 期
Clinical Observation of Shengui Capsule Intervention in Heart Failure with Preserved Ejection Fractioheart failure with preserved ejection fractionITMCTR2200005794Dongzhimen Hospital, Beijing University of Chinese Medicine
尚未招募
4 期
Clinical Study on Xuesaitong Soft Capsule for Patients with Unstable Angina Pectoris: a Randomized Controlled Trialunstable angina pectorisITMCTR2000003228Xiyuan Hospital of China Academy of Traditional Chinese Medicine
尚未招募
2 期
Role of pippali churna orally with udumber tail pichu in management of kaphaj yonivyapadCTRI/2021/01/030276Dr Jayashree Abhijit Sawashe